Search
Banoxantrone
go.drugbank.com/drugs/DB04975InvestigationalBanoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. … Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation. [A3115]
STC3141
go.drugbank.com/drugs/DB16475InvestigationalSTC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.
Palifosfamide
go.drugbank.com/drugs/DB05668InvestigationalPalifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.
Sisunatovir
go.drugbank.com/drugs/DB15674InvestigationalSisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV).
NLX-P101
go.drugbank.com/drugs/DB05924ExperimentalNLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients. … which is overactive in patients with Parkinson’s disease.
Tivantinib
go.drugbank.com/drugs/DB12200InvestigationalTivantinib has been investigated in Solid Tumors.
INO-4800
go.drugbank.com/drugs/DB15693Investigational[A214475] A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. … INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19.
Zeaxanthin
go.drugbank.com/drugs/DB11176ApprovedInvestigationalZeaxanthin is a most common carotenoid alcohols found in nature that is involved in the xanthophyll cycle. … As a coexistent isomer of lutein, zeaxanthin is synthesized in plants and some micro-organisms.
Zastaprazan
go.drugbank.com/drugs/DB21524InvestigationalZastaprazan is a small molecule drug. The usage of the INN stem '-prazan' in the name indicates that Zastaprazan is a proton pump inhibitor, not dependent on acid activation. … Zastaprazan has a monoisotopic molecular weight of 362.21 Da.
Linaprazan
go.drugbank.com/drugs/DB20602InvestigationalLinaprazan is a small molecule drug. The usage of the INN stem '-prazan' in the name indicates that Linaprazan is a proton pump inhibitor, not dependent on acid activation. … Linaprazan is under investigation in clinical trial NCT00206284 (A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.).